WO2022090893A3 - Escherichia coli compositions and methods thereof - Google Patents

Escherichia coli compositions and methods thereof Download PDF

Info

Publication number
WO2022090893A3
WO2022090893A3 PCT/IB2021/059820 IB2021059820W WO2022090893A3 WO 2022090893 A3 WO2022090893 A3 WO 2022090893A3 IB 2021059820 W IB2021059820 W IB 2021059820W WO 2022090893 A3 WO2022090893 A3 WO 2022090893A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
escherichia coli
compositions
coli compositions
coli
Prior art date
Application number
PCT/IB2021/059820
Other languages
French (fr)
Other versions
WO2022090893A2 (en
Inventor
Annaliesa Sybil Anderson
Laurent Oliver CHORRO
Robert George Konrad DONALD
Jacqueline Marie LYPOWY
Rosalind PAN
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN202180080638.9A priority Critical patent/CN116615439A/en
Priority to IL302362A priority patent/IL302362A/en
Priority to EP21802007.1A priority patent/EP4237428A2/en
Priority to MX2023004912A priority patent/MX2023004912A/en
Priority to JP2023525045A priority patent/JP2023546615A/en
Priority to CA3199610A priority patent/CA3199610A1/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Priority to AU2021368151A priority patent/AU2021368151A1/en
Priority to PE2023001497A priority patent/PE20231934A1/en
Priority to KR1020237017583A priority patent/KR20230096033A/en
Publication of WO2022090893A2 publication Critical patent/WO2022090893A2/en
Publication of WO2022090893A3 publication Critical patent/WO2022090893A3/en
Priority to CONC2023/0005372A priority patent/CO2023005372A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/26—Klebsiella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention relates to compositions that include a polypeptide derived from E. coli or a fragment thereof; and modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof, and methods of use thereof.
PCT/IB2021/059820 2020-10-27 2021-10-25 Escherichia coli compositions and methods thereof WO2022090893A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
IL302362A IL302362A (en) 2020-10-27 2021-10-25 Escherichia coli compositions and methods thereof
EP21802007.1A EP4237428A2 (en) 2020-10-27 2021-10-25 Escherichia coli compositions and methods thereof
MX2023004912A MX2023004912A (en) 2020-10-27 2021-10-25 Compositions and methods thereof.
JP2023525045A JP2023546615A (en) 2020-10-27 2021-10-25 E. coli composition and method thereof
CA3199610A CA3199610A1 (en) 2020-10-27 2021-10-25 Escherichia coli compositions and methods thereof
CN202180080638.9A CN116615439A (en) 2020-10-27 2021-10-25 Coli composition and method thereof
AU2021368151A AU2021368151A1 (en) 2020-10-27 2021-10-25 Escherichia coli compositions and methods thereof
PE2023001497A PE20231934A1 (en) 2020-10-27 2021-10-25 COMPOSITIONS OF ESCHERICHIA COLI AND METHODS THEREOF
KR1020237017583A KR20230096033A (en) 2020-10-27 2021-10-25 Escherichia coli composition and method thereof
CONC2023/0005372A CO2023005372A2 (en) 2020-10-27 2023-04-27 Escherichia coli compositions and methods thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063106077P 2020-10-27 2020-10-27
US63/106,077 2020-10-27
US202163144058P 2021-02-01 2021-02-01
US63/144,058 2021-02-01
US202163254195P 2021-10-11 2021-10-11
US63/254,195 2021-10-11

Publications (2)

Publication Number Publication Date
WO2022090893A2 WO2022090893A2 (en) 2022-05-05
WO2022090893A3 true WO2022090893A3 (en) 2022-06-09

Family

ID=78500672

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/059820 WO2022090893A2 (en) 2020-10-27 2021-10-25 Escherichia coli compositions and methods thereof

Country Status (11)

Country Link
EP (1) EP4237428A2 (en)
JP (1) JP2023546615A (en)
KR (1) KR20230096033A (en)
AU (1) AU2021368151A1 (en)
CA (1) CA3199610A1 (en)
CO (1) CO2023005372A2 (en)
IL (1) IL302362A (en)
MX (1) MX2023004912A (en)
PE (1) PE20231934A1 (en)
TW (1) TW202227467A (en)
WO (1) WO2022090893A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023111907A1 (en) 2021-12-17 2023-06-22 Pfizer Inc. Polynucleotide compositions and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004496A2 (en) * 2000-07-07 2002-01-17 Medimmune, Inc. Fimh adhesin proteins and methods of use
WO2015052344A1 (en) * 2013-10-11 2015-04-16 Glycovaxyn Ag Methods of host cell modification
US20170260240A1 (en) * 2014-09-18 2017-09-14 Raphael Simon Broad spectrum conjugate vaccine to prevent klebsiella pneumoniae and pseudomonas aeruginosa infections
WO2019016187A1 (en) * 2017-07-19 2019-01-24 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2020039359A2 (en) * 2018-08-24 2020-02-27 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2021084429A1 (en) * 2019-11-01 2021-05-06 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2021165928A2 (en) * 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
DE3841091A1 (en) 1988-12-07 1990-06-13 Behringwerke Ag SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (en) 1989-11-10 1993-06-17 Eniricerche Spa SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.
SE466259B (en) 1990-05-31 1992-01-20 Arne Forsgren PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
IT1262896B (en) 1992-03-06 1996-07-22 CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.
AU4230493A (en) 1992-05-06 1993-11-29 President And Fellows Of Harvard College Diphtheria toxin receptor-binding region
ATE188613T1 (en) 1992-06-25 2000-01-15 Smithkline Beecham Biolog VACCINE COMPOSITION CONTAINING ADJUVANTS
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
ES2231770T3 (en) 1993-03-05 2005-05-16 Wyeth Holdings Corporation NEW PLASMIDS FOR THE PRODUCTION OF CRM PROTEIN AND DIFTERIC TOXIN.
HU219056B (en) 1993-03-23 2001-02-28 Smithkline Beecham Biologicals Sa Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
ATE420171T1 (en) 1994-07-15 2009-01-15 Univ Iowa Res Found IMMUNOMODULATORY OLIGONUCLEOTIDES
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
DE69838992T2 (en) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Oil-in-water emulsions with saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
AU760549B2 (en) 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
PL354714A1 (en) 1998-04-09 2004-02-09 Smithkline Beecham Biologicals S.A. Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DE69935606T9 (en) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. ADJUVANCE SYSTEMS AND VACCINE
JP4689044B2 (en) 1998-12-21 2011-05-25 メディミューン，インコーポレーテッド Streptococcus pneumoniae proteins and immunogenic fragments for vaccine use
KR100802198B1 (en) 1998-12-23 2008-02-11 샤이어 바이오켐 인코포레이티드 Novel Streptococcus antigens
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
US7776343B1 (en) 1999-02-17 2010-08-17 Csl Limited Immunogenic complexes and methods relating thereto
CZ303653B6 (en) 1999-03-19 2013-01-30 Smithkline Beecham Biologicals S. A. Immunogenic composition
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
WO2000062800A2 (en) 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
JP2003509452A (en) 1999-09-24 2003-03-11 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム Adjuvant containing polyoxyethylene alkyl ether or ester and at least one nonionic surfactant
EP1221971A2 (en) 1999-09-24 2002-07-17 SmithKline Beecham Biologics SA Use of the combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
WO2001098334A2 (en) 2000-06-20 2001-12-27 Shire Biochem Inc. Streptococcus antigens
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
AU2002351623A1 (en) 2001-12-20 2003-07-09 Shire Biochem Inc. Streptococcus antigens
US8084235B2 (en) 2003-03-13 2011-12-27 Glaxosmithkline Biologicals S.A. Purification process for bacterial cytolysin
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
EP1776105A2 (en) 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
EP1781325A2 (en) 2004-07-18 2007-05-09 CSL Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
CN102716480B (en) 2005-04-08 2023-03-21 惠氏有限责任公司 Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
EP2687228B1 (en) 2007-06-26 2017-07-19 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
WO2010125480A1 (en) 2009-04-30 2010-11-04 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
HUE041381T2 (en) 2012-08-16 2019-05-28 Pfizer Glycoconjugation processes and compositions
JP6446377B2 (en) 2013-03-08 2018-12-26 ファイザー・インク Immunogenic fusion polypeptide
US20200002727A1 (en) 2017-02-17 2020-01-02 Lonza Ltd. Multi-site specific integration cells for difficult to express proteins

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004496A2 (en) * 2000-07-07 2002-01-17 Medimmune, Inc. Fimh adhesin proteins and methods of use
WO2015052344A1 (en) * 2013-10-11 2015-04-16 Glycovaxyn Ag Methods of host cell modification
US20170260240A1 (en) * 2014-09-18 2017-09-14 Raphael Simon Broad spectrum conjugate vaccine to prevent klebsiella pneumoniae and pseudomonas aeruginosa infections
WO2019016187A1 (en) * 2017-07-19 2019-01-24 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2020039359A2 (en) * 2018-08-24 2020-02-27 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2021084429A1 (en) * 2019-11-01 2021-05-06 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2021165928A2 (en) * 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KHATUN FARJANA ET AL: "Immunology of carbohydrate-based vaccines", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM , NL, vol. 165, 1 January 2020 (2020-01-01), pages 117 - 126, XP086397533, ISSN: 0169-409X, [retrieved on 20200419], DOI: 10.1016/J.ADDR.2020.04.006 *
KNIREL YURIY: "Structure of O-Antigens", INTERNET CITATION, 12 December 2019 (2019-12-12), pages 41 - 115, XP002796452, Retrieved from the Internet <URL:http://glycoscience.ru/Knirel/Papers/13578_O-antigens_Book_2011.pdf> *

Also Published As

Publication number Publication date
CA3199610A1 (en) 2022-05-05
CO2023005372A2 (en) 2023-05-19
EP4237428A2 (en) 2023-09-06
WO2022090893A2 (en) 2022-05-05
AU2021368151A8 (en) 2023-06-22
AU2021368151A1 (en) 2023-06-01
IL302362A (en) 2023-06-01
JP2023546615A (en) 2023-11-06
PE20231934A1 (en) 2023-12-01
TW202227467A (en) 2022-07-16
MX2023004912A (en) 2023-05-16
KR20230096033A (en) 2023-06-29

Similar Documents

Publication Publication Date Title
MX2022005252A (en) Escherichia coli compositions and methods thereof.
WO2021165928A3 (en) Escherichia coli compositions and methods thereof
MX2022002111A (en) Novel anti-cldn18.2 antibodies.
WO2022090893A3 (en) Escherichia coli compositions and methods thereof
MX2021008592A (en) Trem compositions and uses thereof.
IL286467A (en) Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
NO20063521L (en) Mixtures, Methods and Applications of a New Peptide Family
WO2016210370A3 (en) Synthetic peptide compounds and methods of use
CO2021001926A2 (en) Escherichia coli compositions and methods
MX2022014896A (en) Anti-cldn18.2 antibodies and diagnostic uses thereof.
MX2023011400A (en) Immunogenic compositions.
MX2021015961A (en) Novel molecules.
WO2018101595A3 (en) Escherichia coli bacteriophage esc-cop-9 and use for inhibiting proliferation of pathogenic escherichia coli thereof
NZ751995A (en) Modified factor h binding protein
WO2017168414A8 (en) Iron chelators and combination thereof for the treatment of wolfram syndrome 2
EA201892254A1 (en) EXTRACT OF TOBACCO SHEET AND ITS APPLICATION FOR THE TREATMENT OF TOBACCO DEPENDENCE
WO2021226037A8 (en) Treatment of viral infections
MX2022014899A (en) Lfa3 variants and compositions and uses thereof.
BR112022014844A2 (en) TREATMENT OF DISEASES ASSOCIATED WITH PANX1
WO2021021603A3 (en) Engineered hcv e2 immunogens and related vaccine compositions
WO2018074498A8 (en) Recombinant proteins derived from genus limulus, and dna molecules encoding same
WO2019222502A8 (en) Endolysins active against bacillus bacteria, pharmaceutical compositions, and methods relating thereto
PH12019501164A1 (en) Trehalose phosphorylase
BR112022006550A2 (en) ESCHERICHIA COLI COMPOSITIONS AND ITS METHODS
MX2020008295A (en) Polypeptide, compositions and uses thereof.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21802007

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3199610

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2023525045

Country of ref document: JP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112023007431

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112023007431

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20230420

ENP Entry into the national phase

Ref document number: 20237017583

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 202180080638.9

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2021368151

Country of ref document: AU

Date of ref document: 20211025

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2021802007

Country of ref document: EP

Effective date: 20230530

WWE Wipo information: entry into national phase

Ref document number: 523440536

Country of ref document: SA